Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AR
Artelo Biosciences, Inc. Common Stock
ARTL
Volume
11.68K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AR
ARTL
AR
Artelo Biosciences, Inc. Common Stock
ARTL
News
·
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
Mkt Cap
$1.5M
Volume
11.68K
Next Earnings
November 11th
Chart
Financials
Earnings
News
About
Insider
Filings
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
Artelo Biosciences reminds shareholders to submit proxies in advance of its Annual Meeting scheduled for July 17, 2026. The company emphasizes that proxy submissions help establish quorum regardless of voting direction, and notes that failure to achieve quorum could result in meeting adjournment and additional expenses.
GlobeNewswire Inc. · Jul 14, 2026
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Artelo Biosciences completed a private placement raising $11.0 million through the sale of 3.2 million shares and warrants at $3.45 per share. The company plans to use proceeds for working capital, general corporate purposes, and bridge debt repayment. Warrants could generate an additional $20.4 million if fully exercised.
GlobeNewswire Inc. · Mar 30, 2026
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
Artelo Biosciences, a clinical-stage pharmaceutical company, has priced a public offering of 441,210 common stock shares and pre-funded warrants, expecting to raise approximately $2.0 million to support its therapeutic development efforts.
Benzinga · Sep 30, 2025
Artelo Biosciences Announces Proposed Underwritten Public Offering
Artelo Biosciences is conducting an underwritten public offering of common stock and pre-funded warrants, with R.F. Lafferty & Co., Inc. acting as the sole book-running manager.
GlobeNewswire Inc. · Sep 29, 2025
Cannabinoid Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The cannabinoid agonist market is gaining momentum with expanding medical cannabis legalization and growing clinical validation for treating chronic pain, epilepsy, and inflammatory conditions. Over 20 pharmaceutical companies are actively developing cannabinoid agonist drugs with promising pipeline candidates.
GlobeNewswire Inc. · Jul 10, 2025
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
Artelo Biosciences secured a private placement for $1.425 million, issuing common stock and warrants to fund clinical studies and working capital needs, including potential digital currency investment.
GlobeNewswire Inc. · Jun 26, 2025
Artelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
Artelo Biosciences presented data showing that its FABP5 inhibitor, ART26.12, demonstrated analgesic effects similar to naproxen in a rat model of osteoarthritis pain, with the potential for development as a non-opioid, non-steroidal alternative for chronic OA pain.
GlobeNewswire Inc. · Jun 5, 2025
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
Artelo Biosciences, a clinical-stage pharmaceutical company, announced that its CEO, Gregory D. Gorgas, will participate in a fireside chat at the Maxim Group 2024 Virtual Healthcare Summit on October 16, 2024.
GlobeNewswire Inc. · Oct 9, 2024
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Artelo Biosciences, a clinical-stage pharmaceutical company, announced that its CEO will be participating in the upcoming H.C. Wainwright Global Investment Conference. The company's presentation will be available on-demand, and management will be holding one-on-one meetings with investors.
GlobeNewswire Inc. · Sep 4, 2024
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy ART26.12 shows efficacy in breast cancer-induced bone pain and diabetic neuropathy
GlobeNewswire Inc. · Jun 4, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AR
ARTL
Artelo Biosciences, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
ARTL
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ARTL yet.
Related Tickers
Earnings